Blue­bird bio starts 15 pa­tients on its three mul­ti­mil­lion-dol­lar gene ther­a­pies

Blue­bird bio’s stock $BLUE jumped over 20% on Thurs­day fol­low­ing its first-quar­ter earn­ings re­lease and the an­nounce­ment of 15 pa­tients start­ing on its three ap­proved gene ther­a­pies: Zyn­te­glo, Skysona and Lyf­ge­nia.

The com­pa­ny wrote in its fi­nan­cial re­port that 15 pa­tients had com­plet­ed starts on its ex­pen­sive gene ther­a­pies: 11 on Zyn­te­glo for trans­fu­sion-de­pen­dent tha­lassemia, three on Skysona for cere­bral adrenoleukody­s­tro­phy and one on Lyf­ge­nia for sick­le cell. Blue­bird ex­pects 85 to 105 to­tal pa­tient starts across its port­fo­lio this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER